Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Cryer

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Current Medical Research and Opinion|December 15, 2010
Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritisB Cryer, X Luo, A R Assaf, et al.
The American Journal of Physiology|December 22, 1999
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid refluxM Feldman, B Cryer, D Sammer, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patientsL Laine, S P Curtis, B Cryer, et al.
Gastroenterology|April 1, 1996
Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective studyM Feldman, B Cryer, K E McArthur, et al.
Cancer Research|November 4, 2000
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cellsR F Souza, K Shewmake, D G Beer, et al.
The American Journal of Gastroenterology|December 1, 1992
Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationships with demographics, environmental, and histological factors, including Helicobacter pyloriB Cryer, T W Faust, M Goldschmiedt, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2005
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug useB Cryer, P Miller, R A Petruschke, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2006
Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditionsD C Metz, G M Comer, E Soffer, et al.
Current Medical Research and Opinion|December 23, 2003
Disintegration/dissolution profiles of copies of Fosamax (alendronate)S Epstein, B Cryer, S Ragi, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Current Medical Research and Opinion|December 15, 2010
Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritisB Cryer, X Luo, A R Assaf, et al.
The American Journal of Physiology|December 22, 1999
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid refluxM Feldman, B Cryer, D Sammer, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patientsL Laine, S P Curtis, B Cryer, et al.
Gastroenterology|April 1, 1996
Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective studyM Feldman, B Cryer, K E McArthur, et al.
Cancer Research|November 4, 2000
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cellsR F Souza, K Shewmake, D G Beer, et al.
The American Journal of Gastroenterology|December 1, 1992
Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationships with demographics, environmental, and histological factors, including Helicobacter pyloriB Cryer, T W Faust, M Goldschmiedt, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2005
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug useB Cryer, P Miller, R A Petruschke, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2006
Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditionsD C Metz, G M Comer, E Soffer, et al.
Current Medical Research and Opinion|December 23, 2003
Disintegration/dissolution profiles of copies of Fosamax (alendronate)S Epstein, B Cryer, S Ragi, et al.
Pageof 4